Federated Investors Inc. PA boosted its stake in shares of Glaukos Corp (NYSE:GKOS) by 0.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 791,568 shares of the medical instruments supplier’s stock after buying an additional 234 shares during the period. Federated Investors Inc. PA’s holdings in Glaukos were worth $51,373,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Rehmann Capital Advisory Group bought a new stake in shares of Glaukos in the 3rd quarter worth $63,000. NumerixS Investment Technologies Inc bought a new stake in shares of Glaukos in the 2nd quarter worth $127,000. Great West Life Assurance Co. Can increased its holdings in shares of Glaukos by 112.0% in the 2nd quarter. Great West Life Assurance Co. Can now owns 4,240 shares of the medical instruments supplier’s stock worth $172,000 after purchasing an additional 2,240 shares in the last quarter. Valeo Financial Advisors LLC bought a new stake in shares of Glaukos in the 2nd quarter worth $183,000. Finally, Prudential Financial Inc. bought a new stake in shares of Glaukos in the 3rd quarter worth $203,000.

A number of research firms have commented on GKOS. Stephens lifted their target price on Glaukos from $57.00 to $70.00 and gave the stock an “overweight” rating in a report on Monday, September 10th. Berenberg Bank began coverage on Glaukos in a report on Thursday, August 30th. They issued a “hold” rating and a $57.00 target price for the company. Wells Fargo & Co lifted their target price on Glaukos from $50.00 to $74.00 and gave the stock an “outperform” rating in a report on Thursday, August 30th. JPMorgan Chase & Co. raised Glaukos from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $42.00 to $75.00 in a report on Wednesday, August 29th. Finally, Zacks Investment Research lowered Glaukos from a “hold” rating to a “sell” rating in a report on Friday, November 2nd. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Glaukos presently has a consensus rating of “Buy” and a consensus target price of $58.20.

In other news, Director William J. Phd Link sold 14,475 shares of the firm’s stock in a transaction on Tuesday, November 13th. The stock was sold at an average price of $58.01, for a total value of $839,694.75. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Joseph E. Gilliam sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $60.03, for a total value of $300,150.00. Following the completion of the transaction, the chief financial officer now owns 86,117 shares in the company, valued at $5,169,603.51. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 63,075 shares of company stock worth $3,653,652. Company insiders own 11.60% of the company’s stock.

GKOS stock opened at $64.59 on Friday. Glaukos Corp has a 1 year low of $25.25 and a 1 year high of $70.91.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, November 7th. The medical instruments supplier reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.05). The firm had revenue of $43.91 million during the quarter, compared to analysts’ expectations of $41.65 million. Glaukos had a negative return on equity of 9.26% and a negative net margin of 8.13%. The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the business earned $0.04 earnings per share. Equities analysts predict that Glaukos Corp will post -0.56 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/federated-investors-inc-pa-has-51-37-million-position-in-glaukos-corp-gkos/2689556.html.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Further Reading: What is a Swap?

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.